TOPIGEN Pharmaceuticals Inc., an emerging biopharmaceutical company specializing in respiratory disorders, today announced it has initiated a Phase II clinical trial of TPI-1020 in asthmatic smokers. This study is part of an overall clinical plan for the development of TPI-1020, an inhaled corticosteroid for chronic obstructive pulmonary disease (COPD).
